Dianthus Therapeutics, Inc.
DNTH
$78.86
-$0.04-0.05%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -28.28% | 105.18% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -28.28% | 105.18% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -28.28% | 105.18% | |||
| SG&A Expenses | 20.88% | -7.60% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 71.63% | 15.84% | |||
| Operating Income | -72.61% | -15.35% | |||
| Income Before Tax | -75.25% | -16.24% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -75.25% | -16.24% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -75.25% | -16.24% | |||
| EBIT | -72.61% | -15.35% | |||
| EBITDA | -72.66% | -15.37% | |||
| EPS Basic | -47.28% | -10.18% | |||
| Normalized Basic EPS | -40.14% | -13.72% | |||
| EPS Diluted | -47.28% | -10.18% | |||
| Normalized Diluted EPS | -40.14% | -13.72% | |||
| Average Basic Shares Outstanding | 18.99% | 5.50% | |||
| Average Diluted Shares Outstanding | 18.99% | 5.50% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||